Screener
Gyre Therapeutics, Inc. GYRE Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $43,287 | $49,192 |
| Short-term bank deposits | 14,058 | 15,355 |
| Short-term investment | 17,451 | 28,085 |
| Notes receivable | 232 | 5,638 |
| Accounts receivables, net | 27,760 | 31,078 |
| Other receivables from GNI | 255 | 230 |
| Inventories, net | 11,428 | 10,171 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Gyre Therapeutics, Inc. (GYRE) reported cash, cash equivalents, and marketable securities of $17.45M in Q2 2026.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Gyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude